EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
-0.1194 (-5.40%)
At close: 3:48PM EST
Stock chart is not supported by your current browser
Previous Close2.2094
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.0700 - 2.2178
52 Week Range1.4800 - 7.7700
Avg. Volume475,861
Market Cap295.384M
Beta (3Y Monthly)2.83
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).

  • ACCESSWIRE9 days ago

    These 4 Marijuana Stocks Could Spark Activity

    CORAL GABLES, FL / ACCESSWIRE / January 8, 2019 / The beginning of the new year has already gotten off to a swift start for growth in the marijuana industry. With the new year in full swing, Leafbuyer Technologies Inc (OTC:LBUY), Emerald Health Therapeutics Inc (EMHTF), Tilray Inc (TLRY), and HEXO Corp (OTC PINK: HYYDF) (HEXO.TO) represent 4 pot stocks that are heating up on Tuesday. Leafbuyer Technologies Inc (OTC:LBUY) is a company you may not have heard of, but could greatly benefit from looking into.

  • ACCESSWIRE10 days ago

    These 4 Marijuana Stocks Are Bringing The Heat

    CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The cannabis industry has been notoriously successful over the course of the past several years. With the recent increase in capital and sheer amount of businesses entering the market, the nascent sector has seen unprecedented growth. As public opinion surrounding cannabis becomes increasingly more favorable, the marijuana industry may begin to present an appealing opportunity for investors looking into space.

  • Supreme Cannabis’ Target Price Changed in December
    Market Realist28 days ago

    Supreme Cannabis’ Target Price Changed in December

    Investors (MJ) have even lost money in Aphria (APHA), Emerald Health (EMHTF), and Aurora Cannabis (ACBFF), which have lost 64%, 60%, and 37% during the same period, respectively. Analysts’ consensus target price for Supreme Cannabis remained unchanged month-over-month at 3.63 Canadian dollars. The stock closed at ~1 Canadian dollars on December 19, which was at a discount of nearly 72.5%.

  • Say What? A Marijuana Stock Buying Back Its Shares
    Motley Foollast month

    Say What? A Marijuana Stock Buying Back Its Shares

    This newly public pot stock just announced a $50 million share buyback.

  • GlobeNewswirelast month

    Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada

    OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.

  • 3 Events That Defined Pot Stock Emerald Health Therapeutics' 2018
    Motley Foollast month

    3 Events That Defined Pot Stock Emerald Health Therapeutics' 2018

    This has been a big year for production and product line expansion, but it doesn't necessarily make this marijuana stock a buy.

  • GlobeNewswirelast month

    Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

    OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.

  • Canopy Growth to Get Extract Supply from MediPharm Labs
    Market Realist2 months ago

    Canopy Growth to Get Extract Supply from MediPharm Labs

    On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs, in which the latter will supply up to 900 kilograms of cannabis extract to Canopy Growth and its subsidiaries for sale. Initially, Canopy Growth committed to a minimum purchase of 450 kilograms, which could later be extended to another 450 kilograms.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down

    OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.

  • ACCESSWIRE2 months ago

    Emerald Health is a Leader in the Canadian Cannabis Market with Huge Growing Capacity Planned

    NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Emerald Health Therapeutics, Inc. (EMHTF), a licensed Canadian producer of cannabis. From an industry perspective, the recent legalization of cannabis sales for adult recreational use in Canada was a watershed moment for the entire industry and the Company.

  • November Update: Analysts’ Views of Supreme Cannabis
    Market Realist2 months ago

    November Update: Analysts’ Views of Supreme Cannabis

    Supreme Cannabis (SPRWF) is among the worst performers in the sector so far this year. The company’s stock closed nearly 39% lower YTD, which is similar to Emerald Health (EMHTF), which declined by nearly 43% so far this year as of November 19. Let’s look at how the analysts’ price targets and recommendations have changed in November.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Appoints Agro-Biotech President

    VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.

  • GlobeNewswire2 months ago

    MediPharm Labs Corp. Receives Sales Licence from Health Canada

    MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (LABS.V) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. “This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.

  • ACCESSWIRE2 months ago

    Marijuana Stocks Rally Into Thursday Morning After Sessions News: Integrated Cannabis Company (OTC: ICNAF) (CSE: ICAN), Aphria, Emerald Health

    CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Marijuana stocks have seen a surge of attention this year. This event has been well received by the public markets as many marijuana stocks have positively reacted to this news. Sessions, who has been a staunch adversary of the legalization of cannabis, took a very conservative approach when broaching the subject.

  • ACCESSWIRE2 months ago

    Cannabis and Stem Cells Firms That Could Explode

    HENDERSON, NV / ACCESSWIRE / November 8, 2018 / A major stem cell report was released today. Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments

    OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.

  • 3 Marijuana Growing Stocks With the Highest Risk
    Motley Fool2 months ago

    3 Marijuana Growing Stocks With the Highest Risk

    There's more to investing in pot stocks than peak production estimates.

  • ACCESSWIRE3 months ago

    Stocks That Could Run Hyperbolic

    HENDERSON, NV / ACCESSWIRE / October 23, 2018 / We have several stocks on our radar for a big week. One that is jumping off the screen CleanSpark, Inc. (CLSK). If you look at their recent filings you'll ...